A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Trial Profile

A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Neratinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Brain metastases; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing activity of neratinib + capecitabine in patients of cohort 3a (n=37, no prior lapatinib or capecitabine), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2017 Results from this trial published in a Puma Biotechnology Media Release.
    • 03 Jun 2017 According to a Puma Biotechnology, results from the second cohort and cohort 3B (prior lapatinib-treated) will be presented at a forthcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top